Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 0.76 |
| ▸ | MTOR | P42345 | 16/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.76 |
| ▸ | ATR | Q13535 | 9/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.76 |
| ▸ | PRKDC | P78527 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17272576 | 0.91 | MTOR (0.77) | ATMMTORPIK3CAATRKCNH2 | |
| SCHEMBL22675397 | 0.87 | ATM (0.85) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL18318389 | 0.87 | ATM (0.68) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL29355614 | 0.86 | ATM (1.00) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL17246146 | 0.86 | ATM (1.00) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL17246483 | 0.86 | ATM (1.00) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL30410610 | 0.86 | ATM (1.00) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL20915002 | 0.86 | ATM (0.79) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL17242505 | 0.86 | ATM (1.00) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL17242511 | 0.86 | ATM (1.00) | ATMMTORPIK3CAATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822111-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885MTOR 393/4885PIK3CA 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.